Triple antithrombotic therapy was associated with a 3- to 6-fold increase in bleeding events in 8 of 12 reviewed studies, with limited evidence of additional benefit in reducing ischemic events.
Does triple antithrombotic therapy (aspirin, a thienopyridine, and warfarin) increase bleeding risk or improve ischemic outcomes compared to dual antithrombotic therapy in patients with vascular disease?
Triple antithrombotic therapy is associated with a significant increase in bleeding risk without consistent evidence of ischemic benefit, highlighting the need for individualized clinical judgment.
OBJECTIVE: To review the rationale, clinical practice guideline recommendations, and clinical trial data describing bleeding and clinical outcomes associated with the use of the combination of aspirin, a thienopyridine, and warfarin. DATA SOURCES: An English-language literature search was conducted using MEDLINE (1966-March 2008) and the search terms aspirin, clopidogrel, ticlopidine, thienopyridine, warfarin, antiplatelet, anticoagulant, myocardial infarction, atrial fibrillation, and percutaneous coronary intervention (PCI). Additional references were identified by reviewing reference citations of articles retrieved. STUDY SELECTION AND DATA EXTRACTION: Applicable data were extracted from published reports and studies that included either clinical outcomes or adverse events. DATA SYNTHESIS: Clinical guidelines recommend the combination of antiplatelets and anticoagulants based largely on writing committee consensus. To date, only one randomized clinical trial has evaluated the safety and efficacy of adding warfarin to dual antiplatelet therapy (ie, triple antithrombotic therapy). Other published data are from case series, observational studies, and case-controlled studies primarily of patients undergoing PCI with intracoronary stent placement. Four of 12 studies reported no increased risk of major bleeding events. In the other 8 studies, a 3- to 6-fold increase in bleeding events was reported with triple antithrombotic therapy. Ischemic events were reported in only 6 of the studies. Only 2 studies observed an additional benefit in the reduction of ischemic events, and 1 study reported worsened ischemic outcomes with the triple antithrombotic regimen compared with dual antithrombotic therapy. CONCLUSIONS: Available guidelines pertaining to the concomitant administration of aspirin, a thienopyridine, and warfarin are based on limited trial data and consensus judgment. Overall, selection of triple antithrombotic therapy for patients with vascular disease is considered a matter of clinical judgment for an individual patient based on the prescriber's perceived balance between the patient's risk for recurrent ischemic events, expected duration of treatment, and patient's risk for bleeding.
Hermosillo et al. (2008) conducted a review in Vascular disease, myocardial infarction, atrial fibrillation, and percutaneous coronary intervention. Triple antithrombotic therapy (aspirin, a thienopyridine, and warfarin) vs. Dual antithrombotic therapy was evaluated on Bleeding and ischemic events. Triple antithrombotic therapy was associated with a 3- to 6-fold increase in bleeding events in 8 of 12 reviewed studies, with limited evidence of additional benefit in reducing ischemic events.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: